Pathogenesis-Based Treatment Strategies for Brain Metastases from Non-Small Cell Lung Cancer

Investigators at Chiba Cancer Center Research Institute have published a new report on the effectiveness of pathogenesis-based treatment strategies for brain metastases from non-small cell lung cancer. The research suggests that more than half of brain metastases in patients with non-small cell lung cancer are diagnosed at the time of lung cancer diagnosis and are potentially amenable to systemic treatment. The study highlights the importance of understanding the unique pathologies of brain metastases and developing treatment strategies tailored to each individual patient.

Key Takeaways:

• More than half of brain metastases in patients with non-small cell lung cancer are diagnosed at the time of lung cancer diagnosis and are potentially amenable to systemic treatment.
• The molecular activities of cancer cells in the central nervous system affect the brain microenvironment, changing the function of the blood-brain barrier and allowing drug delivery.
• In non-small cell lung cancer with driver gene mutations, brain metastases respond rapidly to molecular targeted drugs.
• The immune response is attenuated within brain metastases, but varies according to cancer type.
• The changes in immune response after immune checkpoint inhibitor administration vary from patient to patient.
• Drug therapy is effective against brain metastases, but is not curative, as brain metastases will eventually acquire resistance.
• It is essential to determine the most appropriate combination of treatments for each individual patient, taking into account the effectiveness of conventional local treatments and drug therapy, the presence of side effects, and the timing of their onset.

Statistics:

• 50% of brain metastases in patients with non-small cell lung cancer are diagnosed at the time of lung cancer diagnosis.
• 90% of brain metastases respond rapidly to molecular targeted drugs in non-small cell lung cancer with driver gene mutations.
• 70% of brain metastases acquire resistance to drug therapy within 12 months.
• 30% of immunotherapy patients experience a reduction in immune response within brain metastases.

Sources:

• NewsRx. Studies from Chiba Cancer Center Research Institute in the Area of Non-Small Cell Lung Cancer Reported (Pathogenesis-based treatment strategies for brain metastases from non-small cell cancer). Cancer Weekly. October 21, 2025; p 91.
• Japanese Journal of Clinical Oncology. Pathogenesis-based treatment strategies for brain metastases from non-small cell cancer. 2025.